Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.875p 5.50p 6.25p 5.875p 5.875p 5.875p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.2 -10.8 -1.0 - 68.84

Tissue Regenix Share Discussion Threads

Showing 9051 to 9075 of 9075 messages
Chat Pages: 363  362  361  360  359  358  357  356  355  354  353  352  Older
RBS critic pays £20,000 for billboard criticising bank "Mitchell claims GRG conspired to push Torex Retail into administration before selling it off at a discount price in 2007."
The latest MIT Technology Review: Vol 121 No.6 Nov/Dec 2018 - "The Precision Medicine Issue" makes fascinating reading for anyone with an interest in healthcare trends. Could well inform investing decisions too :)
Today, like many other days recently, TRX was showing as over 6% down without the volume of sales to even remotely justify such a fall. Then, when the market closed, it suddenly reverted to show no changed in the share price. I've noticed this happening with other shares in my portfolio too, mostly AIM or smaller companies. Can anyone shed any light on why prices can temporarily show large drops like this, only to revert to its correct price once the market closes?
Very upbeat video on trading momentum and prospects.....I hope this will start to see traction on the share price as it has been a dog in my portfolio! hxxp://
Good progress finally!
Sbtx RNS boom time.Big rerate to come
This news article, though not mentioning TRX, seems encouraging regarding the company's general activities. ________________________ Organ regeneration could end ‘barbaric̵7; transplants, says Professor Sir Robert Lechler Oliver Moody, Science Correspondent July 14 2018 The Times Regenerative medicine could soon eliminate the need for transplants, the president of the Academy of Medical Sciences believes Organ transplants will be seen as a “barbaric̶1; relic of the past within a generation thanks to scientific advances that could allow patients to regrow their own damaged tissue, one of the foremost authorities in the field has predicted. Professor Sir Robert Lechler, president of the Academy of Medical Sciences, said he expected that over the next two decades researchers would find a way to regenerate organs through stem cells or changes to their genetic machinery. In an interview with The Times, Sir Robert also said: "He was firmly in favour of liberalising the laws on assisted dying, and had asked his children to “shoot” him if he lost “certain faculties”. Unpublished data from an early clinical trial suggested a new treatment could allow many transplant recipients to come off immune-suppressing drugs that leave them vulnerable to bugs. Britain should allow controlled experiments in cutting disease-carrying DNA out of human embryos so that couples can have children free of genetic illnesses. Patients would receive personalised advice on their diets, exercise regimes and other aspects of their lifestyle tailored to their genes, as current guidelines were so general that they were often ignored. In his day job as professor of immunology at King’s College London (KCL), Sir Robert has led ground-breaking research into ways of stopping the body’s immune defences from attacking transplanted organs. He believes, however, that the young discipline of regenerative medicine could soon eliminate the need for transplants. “I really think in 20 years’ time people will think, ‘Good gracious, back then they were taking a kidney out of a brother and putting it into a sister — that’s rather barbaric’,R21; he said. “There will be tissue regeneration in situ, and we won’t need to cut bits out and move them from person to person any more.” Sir Robert pointed to the work of Mauro Giacca, an Italian biologist who will take up a post at KCL in January and has recently shown that pigs can regrow their heart tissue when they are given the right growth and genetic transcription factors. Much of the research originates with the zebrafish, which has a remarkable ability to regenerate its heart thanks to a chemical called fibroblast growth factor 1. A review published in the journal Nature this year also discussed the possibility of restoring lost tissue by harnessing the latent capacity of some organs to grow back when they are damaged. One example of this phenomenon is the skin, which can recruit cells at the base of hairs to nurse the organ back to health if it is injured. The idea is that one day scientists may be able to borrow the tricks that allow skin to heal itself and apply them to organs such as the liver and the kidneys, possibly with a three-dimensional “scaffold̶1; to secure the cells as they develop.
Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott following the appointment of Gareth Hywel Jones as their chief financial officer as well as the big news last month that they've been granted a Human Tissue Authority licence which will allow them to import and distribute their US-made products in the UK market.
04/07/2018 7:00am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Wednesday 4 July 2018 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 5075T Tissue Regenix Group PLC 04 July 2018 Tissue Regenix Group plc Appointment of CFO Leeds, 04 July 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today announces the appointment of Gareth Hywel Jones as Chief Financial Officer (CFO). He will join the Group as CFO, Company Secretary and as an Executive Director on the Board on 30 November 2018. Mr Jones, who will join the Group from Applied Graphene Materials plc (AGM), is an experienced CFO, bringing significant operational, high technology manufacturing and strategic financial expertise gained through roles in UK and US listed businesses as well as private equity. Current interim CFO, Paul Below, will remain with The Group to facilitate an orderly hand-over. Steve Couldwell, CEO Tissue Regenix Group, commented: "We are delighted to announce the appointment of Gareth as our Chief Financial Officer. After an extensive recruitment process, Gareth's proven experience of implementing operational enhancements, divisional business unit management, profit improvement initiatives and strategic commercial planning, in both UK and US quoted companies, will significantly strengthen our leadership team. I look forward to welcoming Gareth to the Group in November." Gareth Jones, CFO - Designate for Tissue Regenix, commented: "Tissue Regenix is at an exciting inflection point in terms of executing against its commercial growth strategy. With tangible and growing traction in the US markets and multiple EU product launches expected, I look forward to working with the executive team and Board as the Company continues to deliver strong organic growth from its innovative products." Mr Jones qualified as a Chartered Accountant with Pricewaterhouse Coopers in 1993. Full details of Mr Jones' (aged 50) current and past directorships within the last five years are provided below. It is intended that Mr Jones will step down from all other Directorships upon commencement of his position within The Group. Current Directorships Applied Graphene Materials plc, Chief Financial Officer, April 2017 - Present Applied Graphene Materials UK Limited Past Directorships Gardner Denver Group Services Limited, Finance Director of Emco Wheaton Division, September 2013-March 2017 Vireol Bio-Industries plc, Vireol Limited, Finance and Commercial Director October 2006-September 2013 Gareth Jones has no shareholding in the Company. It is intended that the Company will, on or as soon as possible following his appointment grant Gareth options over new ordinary shares in the Company.
channel pirate
Quiet on here whilst we all wait for some good news to be announced. The 16988 shares showing as a "sell" at 10.975p today is actually my "BUY". Sold some of these a little while back and bought them back today £100 cheaper, not a lot I know, but sold a different share yesterday for £800 profit, so thought I would put it toward rounding up my holding here. C'mon Mr Couldwell, an update might just get the share price moving in the right direction again.
channel pirate
Tissue Regenix will be presenting to investors at the Proactive One2One Healthcare Forum taking place on the evening of 17th May in London. For details and registration, please click here:
Well, Woodford has bought more; so at least there's one person, other than me, keeping the faith!
Is they the house broker. If so it don't mean jack
swiss paul
Agree graham, and I am sitting with a few more than that in the hope of a good end value !!
channel pirate
Possibly correct, CP, but in the larger scheme of shareholdings a near quarter of a million shares may be large in numbers, but is not that significant in terms of end value.
Delayed SELL from yesterday of 241,159 @ 8.10p showing up today. Now is that someone who is desperate for "cash" or a bit of knowledge of what is coming in the Results next Monday ??
channel pirate
Did any investors ever get paid any compensation for this bunch of crooks? I lost a small fortune based on falsehoods! Scandelous. Would be interested to know who took it further and got reimbursed.
New Hardman Report - posted on LSE by "sandhopper" hxxp://
channel pirate
My wife is a nurse and she has mentioned before how some wounds are hard to heal and can become long term problems. While not a clinician myself, I do wonder why Dermapure is not flying off the shelves. Having followed its development from the sidelines, it sounds like an exceptionally effective product - as confirmed today and one that is already changing surgeons behaviour. Is it too expensive? I am waiting for the day this really starts to take off, as I am sure it will.
2 X RNS's today !! Let's hope we get some positive share price lifting results on 19th March then: 26/02/2018 7:01am UK Regulatory (RNS & others) Tissue Regenix (LSE:TRX) Intraday Stock Chart Today : Monday 26 February 2018 Click Here for more Tissue Regenix Charts. TIDMTRX RNS Number : 8568F Tissue Regenix Group PLC 26 February 2018 Tissue Regenix Group plc Notice of Results Leeds, 26 February 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces it will release its unaudited preliminary results for the year ended 31 December 2017 on Monday 19 March. Further information regarding an analyst call will follow in due course. For more Information: Tissue Regenix Group plc Tel: 0330 Caitlin Pearson Head of Communications 430 3073 / 07920272 441 ---------------------------------------- ------------ Jefferies International Ltd Tel: 020 Simon Hardy / Christopher Binks 7029 8000 ---------------------------------------- ------------ FTI Consulting Tel: 0203 Brett Pollard / Mo Noonan/ Rob Winder 727 1000
channel pirate
Sound familiar? From Mr C on Lemon fool: Sinclair Pharma (SPH) drops US distributor for Silhouette InstaLift end March, by mutual agreement. "Sinclair will pay to Thermi a one-off, undisclosed payment for the early termination and will regain the full US distribution rights for the Products." Why the payment if the termination is mutual? "Advanced discussions with potential US partners are ongoing and we expect to enter into an alternative arrangement effective from 1 April". SPH: Price=22. Cap=111m. F/C for current FY*: EPS= -1.31, Prospective PE= -16.8, Revenue=NA. Sinclair Pharma is a specialty pharmaceutical company focused on Dermatology, in particular - Aesthetics, Wound care, and Skin care. How is the U side of the business?
swiss paul
Steve Couldwell [new CEO] and Neil Hunt [Knee surgeon] speak on first vid. Innovations in soft tissue regenerative medical technology – Tissue Regenix Healing skeletal defects through regenerative medicine – CellRight Technologies Https://
I kept the faith, and held on: hopefully the reward will come this year, as things do now seem to be stirring!
Chat Pages: 363  362  361  360  359  358  357  356  355  354  353  352  Older
Your Recent History
Tissue Reg..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190119 23:36:31